TAM Receptor

TAM-IN-2 is an inhibitor of TAM.

Bemcentinib-d8 (R428-d8) is the deuterium-labeled form of Bemcentinib. Bemcentinib (R428) is an orally active, selective Axl inhibitor with an IC50 of 14 nM. It inhibits cancer cell migration and invasion. In cells, its selectivity for Axl is over 100-fold greater than for Abl, and over 50- and 100-fold greater for the TAM family kinases Mer and Tyro3, respectively. Bemcentinib can prevent tumor spread in metastatic breast cancer models and extends survival.

Gilteritinib (ASP2215) is a potent inhibitor at the FMS-related tyrosine kinase 3 (FLT3) and AXL tyrosine kinase receptors (IC50 = 0.29 nM and <1 nM,

UNC2250 is an effective and specific Mer inhibitor (IC50=1.7 nM).

UNC2881 is a specific Mer tyrosine kinase inhibitor (IC50: 4.3 nM). It is about 83- and 58-fold higher selectivity than Axl and Tyro3, respectively.

SGI-7079: selective Axl inhibitor; hinders tumor growth dose-dependently; may target EGFR inhibitor resistance.

LDC1267 is a excellently specific TAM(Tyro3, Axl and Mer) kinase inhibitor, for Mer( IC50<5 nM), Tyro3(IC50=8 nM), and Axl(IC50=29 nM).

Cabozantinib hydrochloride (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt4 (IC50s: 0.035, 1.3, 4.6, 7 and 6

UNC2541 is a potent and Mer tyrosine kinase (MerTK)-specific inhibitor.

2-D08 is a synthetic flavone that inhibits sumoylation, also inhibits Axl with an IC50 of 0.49 nM.2-D08 showed anti-aggregatory and neuroprotective effect.

Bemcentinib (R428) is a selective inhibitor of Axl (IC50: 14 nM) and has been investigated for the treatment of NSCLC.

RU-301 is a novel pan-tam inhibitor

UNC569 selectively inhibits kidney URAT1, regulating uric acid excretion and aiding gout patient's uric balance.

BMS 777607 (BMS 817378) is a Met-related inhibitor for c-Met/Axl/Ron/Tyro3. BMS-777607 has been investigated for the basic science of Malignant Solid Tumour.

Cabozantinib (XL184) is a multi-targeted tyrosine kinase receptor inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50=0.035/1.3/4.6/7/11.3 nM).

XL092 (JUN04542) is an Axl Mer cMet KDR inhibitor for the treatment of Axl and Mer receptor tyrosine kinase- dependent disorders.

CEP-40783 (RXDX-106) is an effective, specific and orally active AXL/c-Met inhibitor (IC50: 7/12 nM). It also inhibits MER and TYRO3 (IC50: 29/19 nM).

Ningetinib Tosylate is an orally bioavailable tyrosine kinase inhibitor with IC50s of <1.0, 1.9 and 6.7 nM for Axl, VEGFR2, and c-Met, respectively.

ONO-7475 is an inhibitor with high specificity for anexelekto and MER tyrosine kinase

DS-1205: AXL kinase inhibitor (IC50=1.3 nM), also targets MER, MET, TRKA (IC50s: 63, 104, 407 nM), hinders cell migration and tumor growth.